Oncology Venture

Oncology Venture Up-date

Mon, Nov 09, 2015 17:32 CET

Hoersholm, Denmark; November 9th, 2015 – Oncology Venture Sweden AB (OV:ST) up-dates information about drug candidates in the pipeline.Irofulven: The screening part of the trial is expected to include its first patients in Q4 2015. Following the production of Irofulven, which has already been initiated, first patient treated is expected in late Q2-Q3 2016. Production of Irofulven has been initiated.APO010: old drug on stock may be useful in the planned trial of Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL). This causes potential large initial savings on production costs. 5

3 abstracts to be presented at International Cancer meeting in Boston

Fri, Sep 04, 2015 12:48 CET

Oncology Venture announces that three abstracts have been accepted for presentation on the AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics in November 5-9 2015, Hynes Convention Center, Boston, Massachusetts.“Oncology Ventures in-licensed DRP™ - Drug Response Predictor matching the cancer drug to the responding patient has gained considerable interest from experts. The presentation of three abstracts at this well recognized international high level cancer conference is very encouraging for Oncology Ventures use of DRP™ in precision medicine” said CEO, MD,

Share

Oncology Venture Up-date

3 abstracts to be presented at International Cancer meeting in Boston